Semaglutide or Tirzepatide: Which Should You Start On?
Semaglutide against tirzepatide: efficacy from the STEP and SURMOUNT trials, side effects, cost, availability, and which one fits you.
By Ruth Calder, Enforcement Editor
Our methodology sets out how these guides get researched and kept current.
Looking for a provider? Our 2026 comparison of the leading GLP-1 telehealth sellers is a click away.
Compare GLP-1 Providers →Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Semaglutide and tirzepatide are the two most effective weight-loss medications ever brought to market. Both are weekly injections, both are sold under famous brand names (Ozempic, Wegovy, Mounjaro, Zepbound), and both can produce double-digit body-weight loss in clinical trials. But they are not the same drug, and in 2026 the head-to-head data is finally clear enough to give patients a real answer.
Below, the two drugs are set side by side on efficacy, side effects, cost, availability, and the kind of patient each suits best, with every clinical claim sourced. If you want to go straight to telehealth providers that offer one or both, our best GLP-1 providers ranking lists them. Read the efficacy section first, though, because it changes what to look for in a seller.
Key Takeaways
- Tirzepatide produces more weight loss on average. SURMOUNT-1 showed 20.9% mean weight loss at the highest dose vs 14.9% for semaglutide in STEP-1.
- The mechanism is different. Semaglutide is a single-pathway GLP-1 agonist; tirzepatide is a dual GIP/GLP-1 "twincretin."
- Side effect profiles are similar but tirzepatide users report slightly more GI symptoms in the early titration weeks.
- Brand-name cost is comparable: list prices run about $1,086–$1,349 a month, and both makers now sell for cash well below list. Compounded availability differs.
- Insurance coverage depends on your plan's formulary, and some plans prefer one drug over the other.
- Best for most patients seeking maximum weight loss: tirzepatide, if available and affordable.
- Best for patients with cardiovascular risk: semaglutide. Wegovy is FDA-approved to cut heart attacks, strokes and cardiovascular deaths in people who already have cardiovascular disease plus obesity or overweight. Tirzepatide holds a cardiovascular indication only as Mounjaro, and only for people with type 2 diabetes whose cardiovascular risk is high; Zepbound has none. Two real-world studies that compared the drugs on heart outcomes reached different answers.
What Are Semaglutide and Tirzepatide?
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. FDA approval came in two steps: 2017 for type 2 diabetes, sold as Ozempic, then 2021 for chronic weight management, sold as Wegovy. It mimics the natural hormone glucagon-like peptide-1, which signals satiety to the brain and slows the rate at which the stomach empties.
Tirzepatide, from Eli Lilly, is a dual GIP/GLP-1 receptor agonist. It activates two incretin pathways instead of one: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). It was approved for type 2 diabetes (as Mounjaro) in 2022 and for weight management (as Zepbound) in November 2023.
For a deeper dive on the molecule itself, see our full semaglutide drug guide and tirzepatide drug guide.
Efficacy: What the Pivotal Trials Show
In 2026 the headline answer is unambiguous: tirzepatide produces more weight loss on average. Both drugs are still far more effective than anything that came before.
The STEP-1 Trial (Semaglutide)
STEP-1 is the pivotal weight-management trial for semaglutide, and the *New England Journal of Medicine* carried it in 2021. It randomized 1,961 adults with obesity (mean BMI 37.9) for 68 weeks. Everyone got lifestyle intervention; the arms differed only in semaglutide 2.4 mg weekly versus placebo.
- Mean body weight loss (semaglutide): -14.9%
- Mean body weight loss (placebo): -2.4%
- Achieved ≥5% weight loss: 86.4% of semaglutide group vs 31.5% of placebo
- Achieved ≥15% weight loss: 50.5% of semaglutide group vs 4.9% of placebo
The SURMOUNT-1 Trial (Tirzepatide)
SURMOUNT-1 was the analogous pivotal trial for tirzepatide, published in NEJM in 2022. It randomized 2,539 adults with obesity (mean BMI 38.0) to placebo or one of three tirzepatide doses (5 mg, 10 mg, 15 mg) for 72 weeks.
- Mean body weight loss (tirzepatide 15 mg): -20.9%
- Mean body weight loss (tirzepatide 10 mg): -19.5%
- Mean body weight loss (tirzepatide 5 mg): -15.0%
- Mean body weight loss (placebo): -3.1%
- Achieved ≥20% weight loss (15 mg): 57% of patients
The Head-to-Head: SURPASS-2
While STEP-1 and SURMOUNT-1 used different patient populations, the SURPASS-2 trial directly compared tirzepatide against semaglutide in 1,879 adults with type 2 diabetes. Over 40 weeks, tirzepatide 15 mg produced 11.2 kg of weight loss vs 5.7 kg for semaglutide 1 mg, roughly double.
The Side-by-Side
| Outcome | Semaglutide 2.4 mg (trial: STEP-1) | Tirzepatide 15 mg (trial: SURMOUNT-1) |
|---|---|---|
| Mean weight loss | -14.9% | -20.9% |
| Reached ≥5% loss | 86.4% | 91% |
| ≥10% weight loss | 69.1% | 84% |
| ≥15% weight loss | 50.5% | 71% |
| ≥20% weight loss | 32% | 57% |
| Trial duration | 68 weeks | 72 weeks |
Tirzepatide moves the entire distribution to the right. More patients hit every weight-loss threshold, and the average loss is roughly 6 percentage points higher.
Side Effects: Largely Similar
Both drugs share the same dose-limiting side effect: gastrointestinal upset. Nausea, constipation, diarrhea, vomiting, and abdominal discomfort are reported by 30–60% of users at some point during titration. These symptoms usually peak in the days following a dose increase and subside as the body acclimates.
In SURMOUNT-1, adverse events led 4.3%, 7.1% and 6.2% of patients on tirzepatide 5, 10 and 15 mg to stop treatment, against 2.6% on placebo. In STEP-1, 4.5% of semaglutide patients stopped because of gastrointestinal events, against 0.8% on placebo. The two papers report different measures and the trial designs differed, so a direct comparison is imperfect.
For a complete management guide, read our deep dive on managing semaglutide side effects.
Serious (Rare) Risks
Both labels open with the same boxed warning, which concerns thyroid C-cell tumors in rodents, and they list the same serious adverse reactions (acute kidney injury, gallbladder disease, pancreatitis). Two histories rule out both drugs, in the patient or a relative: multiple endocrine neoplasia syndrome type 2, and medullary thyroid carcinoma.
Cost Comparison
| Brand-name list price | Compounded (telehealth) | Insurance-covered | |
|---|---|---|---|
| Semaglutide (Wegovy) | $1,349/mo | $129–$249/mo | Plan co-pay; as little as $25 with the savings card |
| Tirzepatide (Zepbound) | Up to $1,086/mo | $199–$399/mo | Plan co-pay; as little as $25 with the savings card |
Brand-name prices come from manufacturer websites and are list prices before insurance, manufacturer coupons, or pharmacy discounts. Novo Nordisk and Eli Lilly both run savings programs. If your commercial plan covers the drug, the maker's savings card can bring the out-of-pocket cost down to $25/month. Without coverage, both makers sell for cash: Wegovy pens cost $349/month through NovoCare Pharmacy (the Wegovy pill starts at $149), and Zepbound KwikPens or vials cost $299–$449/month through LillyDirect. Our manufacturer coupons guide has the full terms.
Compounded versions are now made by state-licensed 503A pharmacies for individual patients and dispensed through telehealth providers like the ones in our best providers ranking. Compounded semaglutide is widely available in 2026; compounded tirzepatide availability has been more volatile because of changes to tirzepatide's FDA shortage list status. Check our drug shortage tracker for current status.
Use our savings calculator to estimate your monthly cost based on your starting medication and desired dose.
Availability in 2026
Both drugs have been off the FDA shortage list since early 2025 (by FDA determination, tirzepatide's shortage ended in late 2024 and semaglutide's in February 2025), which has two consequences:
- Brand-name availability is good. Pharmacies can fill Ozempic, Wegovy, Mounjaro, and Zepbound prescriptions without months-long backorders.
- Compounded availability has tightened. Federal law restricts compounding of drugs not on the FDA shortage list, and the FDA's grace periods for compounders ended in spring 2025. The FDA says 503B outsourcing facilities may not compound either drug from bulk ingredients, and 503A pharmacies may compound copies of an approved drug only for individual patients, not regularly or in large amounts.
That is one reason to choose providers carefully. Our guide to checking a pharmacy and our best provider rankings can help.
Many compounded sellers list both molecules, so choosing between them rarely means choosing a seller. BetterMe Rx and Wholesome Clinic list oral and injectable forms of each, and TeleHealth Med offers them by injection or under the tongue. AZ Health sells both as injections or dissolving tablets at flat monthly prices.
MultiMedRx says it compounds in its own pharmacy, PRIMO Health Partners sells both by the vial on a monthly plan, and TeleHealth Weight Solutions starts patients on a 6- to 10-week course before refills. The Aesthetic Concierge bills every five weeks, and LVNG RX bills month to month.
Who Should Choose Which?
Choose tirzepatide if you...
- Want maximum weight loss and have not responded well to semaglutide
- Have type 2 diabetes alongside obesity (tirzepatide produces stronger A1C reductions)
- Are willing to titrate more slowly to manage GI side effects
- Have access to an in-network insurance plan that covers Zepbound
Choose semaglutide if you...
- Already have established cardiovascular disease (in SELECT, major adverse cardiovascular events fell 20%)
- Are looking for the lower-cost compounded option
- Have already tried semaglutide and tolerated it well
- Live in a state where tirzepatide is harder to access via telehealth
Bottom Line
If the only question is which drug produces more weight loss, the answer is tirzepatide. The SURMOUNT-1 results are dramatic and have been replicated in follow-up trials. But the choice between the two drugs is rarely just about peak efficacy. Cost, insurance, side effect tolerance, cardiovascular history, and provider availability all matter.
For most patients in 2026, the practical decision tree is: try the drug your insurance covers first; if neither is covered, choose based on the compounded pricing offered by a trusted GLP-1 telehealth provider; if both are accessible at similar cost, default to tirzepatide for higher weight loss potential, with a slow titration to manage GI symptoms.
For a deeper look at why Ozempic and Wegovy are technically the same drug, read our Ozempic vs Wegovy guide. For the parallel question on the tirzepatide side, see Mounjaro vs Zepbound.
Sources & methodology — as of October 2026
- 1.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 2.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 3.SURPASS-2 Trial — Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (Frías JP et al.)— New England Journal of Medicine.PMID: 34170647.
- 4.SURMOUNT-2 Trial — Tirzepatide for the Treatment of Obesity in People with Type 2 Diabetes (Garvey WT et al.)— The Lancet.PMID: 37385275.
- 5.SELECT Trial — Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (Lincoff AM et al.)— New England Journal of Medicine.PMID: 37952131.
- 6.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 7.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
Compare the sellers
Ready to compare GLP-1 providers?
Trust, support, availability, the medications carried and what they cost — we rank every major telehealth seller on all five, and refresh it each quarter. Nothing padded.
Compare GLP-1 Providers →Related guides
Ozempic vs Wegovy Price: Why One Costs More
One molecule, semaglutide, sold under two names at different doses and approved by the FDA for different things. We explain the pricing arbitrage and which to choose.
Mounjaro vs Zepbound Cost: Which One Insurance Pays For
Mounjaro and Zepbound are both tirzepatide with different FDA approvals. We compare indication, price and insurance coverage, and which one fits you.
How to Manage Semaglutide Side Effects, From Nausea to Constipation
A sourced guide to semaglutide side effects (nausea, constipation, fatigue, gallbladder, pancreatitis), with practical management steps and red flags.
How GLP-1 Drugs Actually Work in Your Body
How semaglutide and tirzepatide change appetite, gastric emptying and brain signaling, in plain English, and why tirzepatide's dual action matters.
Read our methodology · affiliate disclosure · about us